Today's Daily Dose brings you news about the FDA panel's vote on Correvio Pharma's anti-arrhythmic drug Brinavess; the near-term catalyst of Eloxx Pharma; the phase III trial results of Iterum's Sulopenem in the treatment of complicated intra-abdominal infections, and Xeris Pharma's phase II study results of ready-to-use (RTU) glucagon.
from RTT - Biotech https://ift.tt/38lrJ6N
via IFTTT
No comments:
Post a Comment